Serum Insulin Response After Acute and Chronic Sucralose Ingestion in Healthy Volunteers With Variable Body Mass Index

Healthy Clinical Trial

Official title:

Effect of Acute or Chronic Ingestion of Sucralose on Serum Insulin in Young and Healthy Adults: a Randomized, Double-blind, Placebo-controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03703141
• Other study ID #: 261575
• Status: Completed
• Phase: N/A
• Start date: September 27, 2016
• Est. completion date: June 4, 2018

Study information

• Verified date: October 2018
• Source: Hospital General de México Dr. Eduardo Liceaga
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The consumption of non-caloric sweeteners has increased worldwide; Current publications suggest its consumption associates to insulin resistance.

The present study aims to demonstrate whether acute or chronic sucralose exposure affects insulin or carbohydrate metabolism or alters systemic inflammatory markers and microbiota in young, healthy adults.

In this prospective, randomized, double-blind, placebo-controlled clinical trial, three groups will be included with 30 healthy volunteers each. Group A will receive sucralose 48 mg/ day, group B 96 mg/day and group C plain water as placebo. Subjects will be exposed to acute (one day) and chronic (seventy days) oral sucralose ingestion. After acute or chronic exposure, volunteers will undergo into an Oral Glucose Tolerance Test (OGTT), taking blood samples at -15, 0, 15, 30, 45, 60, 75, 90, 105, 120 and 180 minutes, respectively.

Areas under the curve (AUC) for insulin and glucose, will be calculated from zero to one hundred and eighty minutes as described; for C peptide, glucagon, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide) measure points will be at 0, 30 and 60 minutes only. Differences between one and seventy days AUC means will be compared between the three groups, adjusting for BMI. Besides, initial and final systemic inflammatory markers and inflammatory monocytes levels will be quantified and compare between acute and chronic exposure. Also, a comparison between the percentage of acute and chronic microbiome bacterial population in feces will be made.

Description:

Introduction Overweight and obesity have increased along with the rate of other non-communicable diseases worldwide. At the same time, the consumption of non-caloric sweeteners (NCS) has risen considerably among the general population. Although international organizations such as Joint FAO/WHO Expert Committee on Food Additives (JECFA) has demonstrated NCS are safe; two recent publications suggested its consumption associates with insulin resistance.

Although the authors attributed the metabolic effect to changes in the composition of intestinal microbiota as a consequence of NCS ingestion, these studies lacked a robust clinical methodology, as their design were not randomized, comparative studies and the effect of NCS on systemic inflammation biomarkers were neglected.

Outcomes The present study aims to demonstrate whether acute or chronic sucralose exposure affects insulin or carbohydrate metabolism or alters systemic inflammatory markers and microbiota in young, healthy adults.

Materials and methods It is a prospective, randomized, double-blind, placebo-controlled clinical trial, comparing three groups, with 30 healthy volunteers each, who will receive daily sucralose, for seventy days. After signing off informed consent, the first group will take 48 mg sucralose diluted in 60 mL of water; the second group will receive 96 mg / 60 ml a day, while the last group will receive 60 ml of plain water as placebo.

Inclusion criteria will be either sex, age between 18 and 35 years, with a body mass index (BMI) between 18.5 and 39.0, disease free, with light or moderate physical activity before entering the study, with a HOMA ≤3.8, non-smokers, non-alcohol drinkers, agreeing not to consume neither industrial food nor beverages related to NCS during the study, having Mexican ancestry, living in the Mexico City metropolitan area and signing informed consent to participate in the study.

Exclusion criteria Any acute disease by the time of recruitment, history of Type 1 or 2 diabetes, thyroid disease, adrenal glands disease, insulinoma, malabsorption syndrome, short bowel, HIV, any cancer, liver disease, renal disease, inflammatory bowel disease, have prescribed corticosteroids in the previous three months before enrollment or undergone to bariatric surgery. Having a BMI <18.5 or >39.0, working night shifts, unable to remain at the clinic for at least 5 hours, not accepting to stop consuming industrialized food or beverages containing NCS, not accepting to stop alcohol or tobacco consumption during the study, not consenting to participate, women in childbearing potential without pregnancy control or women pregnant or breastfeeding by the time of enrollment.

Each volunteer will be instructed to drink 60 mL of fluid containing either sucralose or water, every morning before meals for seventy days. Except on day one and day 70, when they will be requested to attend the clinic after fasting at least 8 hours. Two plastic containers to carry stool sample will be provided in advance to each participant and be requested to store a stool sample. At their arrival to the clinic the stool sample will be collected and labeled. Immediately after, they will be asked to drink the corresponding dose to day one or seventy in the presence of the investigators. Once the investigational material be drinking, an Oral Glucose Tolerance Test (OGTT), will be initiated, taking blood samples at

• 15, 0, 15, 30, 45, 60, 75, 90, 105, 120 and 180 minutes, respectively. Analysis Demographics per group will be described initially. Following, areas under the curve (AUC) for insulin and glucose, will be calculated from zero to one hundred and eighty minutes, as the measure points described above; for C peptide, glucagon, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide) measure points will be at 0, 30 and 60 minutes only.

Mean differences of AUCs between one and seventy days will be compared between the three groups, adjusting for BMI. Besides, initial and final systemic inflammatory markers and inflammatory monocytes levels will be quantified and compared between acute and chronic exposure. Additionally, a comparison of changes between the percentage of acute and chronic microbiome population in feces will be made.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 95
• Est. completion date: June 4, 2018
• Est. primary completion date: June 4, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Men or women

• Ages between 18 and 35 years

• Must not have suffered chronic noncommunicable or infectious diseases

• Must have been practicing light-moderate physical activity before the study

• Normal insulin resistance index according to a homeostatic model value of insulin resistance (HOMA-IR) = 3.8

• Must not be smokers

• They must accept not to consume industrialized foods that contain non-caloric sweeteners during their participation in the study and be agree to receive weekly telephone reminders during the protocol

• Must accept not to consume industrialized beverages containing non-caloric sweeteners during their participation in the study

• Do not consume alcoholic beverages during their participation in the study, do not have alcoholism history and have not consumed alcoholic beverages for less than two weeks before entering to the protocol

• Must have Mexican ancestry

• The volunteers, their parents and grandparents must be from Mexico city metropolitan area

• They must sign the letter of inform consent, expressing their desire to participate as volunteers in the study

Exclusion Criteria:

• People who have any kind of serious illness at the time of the selection

• People who have been diagnosed with Diabetes Mellitus type 1 or type 2

• People who have been diagnosed with thyroid disease

• People who have been diagnosed with any adrenal glands disease

• People who have been diagnosed with insulinoma

• People who have been diagnosed with malabsorption syndrome

• People with short bowel history

• People who have been diagnosed with HIV

• People who have been diagnosed with any type of neoplasia

• People who have been diagnosed with acute or chronic liver disease

• People who have been diagnosed with kidney disease with compromise on serum glucose levels

• People who have been prescribed with corticosteroid in the last 3 months before entering to the study

• People who have been prescribed with any type of antibiotic, 4 weeks prior to entering to the protocol

• People who have been prescribed with any type of non-steroidal anti-inflammatory, 4 weeks prior to entering the protocol

• People who do not accept to remain in the Clinical Pharmacology Unit during the required time to carry out the oral glucose tolerance curves (4 hours, plus the preparation time)

• People with night jobs

• People who did not accept to abstain from consuming industrialized products containing non-caloric sweeteners during their participation in the study

• People who refused to abstain from consuming industrialized beverages containing non-caloric sweeteners during their participation in the study

• People who do not accept to abstain from consuming alcoholic beverages during their participation in the study

• People who have undergone bariatric surgery before the study

• People with inflammatory bowel disease history

• People who have smoked at least 3 cigarettes per week in the last 3 months

• People who do not sign the informed consent letter to participate in the study

• Women on reproductive age without contraception therapy.

• Pregnant women

• Women who are breastfeeding at the time of evaluating their admission to the study,

Related Conditions & MeSH terms

• Healthy

Intervention

Dietary Supplement:
• sucralose 48 mg (splenda)/day for ten weeks
volunteers will take sucralose or placebo daily for 70 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hospital General de México Dr. Eduardo Liceaga

References & Publications (26)

Allison DB, Paultre F, Maggio C, Mezzitis N, Pi-Sunyer FX. The use of areas under curves in diabetes research. Diabetes Care. 1995 Feb;18(2):245-50. — View Citation

Börgeson E, Johnson AM, Lee YS, Till A, Syed GH, Ali-Shah ST, Guiry PJ, Dalli J, Colas RA, Serhan CN, Sharma K, Godson C. Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease. Cell Metab. 2015 Jul 7;22(1):125-37. doi: 10.1016/j.cmet.2015.05.003. Epub 2015 Jun 4. — View Citation

Fakhouri TH, Kit BK, Ogden CL. Consumption of diet drinks in the United States, 2009?2010. NCHS Data Brief. 2012 Oct;(109):1-8. — View Citation

Fjære E, Aune UL, Røen K, Keenan AH, Ma T, Borkowski K, Kristensen DM, Novotny GW, Mandrup-Poulsen T, Hudson BD, Milligan G, Xi Y, Newman JW, Haj FG, Liaset B, Kristiansen K, Madsen L. Indomethacin treatment prevents high fat diet-induced obesity and insu — View Citation

Garcia LM, da Silva KS, Del Duca GF, da Costa FF, Nahas MV. Sedentary behaviors, leisure-time physical inactivity, and chronic diseases in Brazilian workers: a cross sectional study. J Phys Act Health. 2014 Nov;11(8):1622-34. doi: 10.1123/jpah.2012-0423. Epub 2014 Apr 11. — View Citation

Glazier RH, Creatore MI, Weyman JT, Fazli G, Matheson FI, Gozdyra P, Moineddin R, Kaufman-Shriqui V, Booth GL. Density, destinations or both? A comparison of measures of walkability in relation to transportation behaviors, obesity and diabetes in Toronto, Canada. PLoS One. 2014 Jan 14;9(1):e85295. doi: 10.1371/journal.pone.0085295. eCollection 2014. Erratum in: PLoS One. 2014;9(3):e91485. Shriqui, Vered Kaufman [corrected to Kaufman-Shriqui, Vered]. — View Citation

Grotz VL, Jokinen JD. Comment on Pepino et al. Sucralose affects glycemic and hormonal responses to an oral glucose load. Diabetes care 2013;36:2530-2535. Diabetes Care. 2014 Jun;37(6):e148. doi: 10.2337/dc13-2972. — View Citation

Grotz VL, Munro IC. An overview of the safety of sucralose. Regul Toxicol Pharmacol. 2009 Oct;55(1):1-5. doi: 10.1016/j.yrtph.2009.05.011. Epub 2009 May 21. Review. — View Citation

Hernández B, Gortmaker SL, Colditz GA, Peterson KE, Laird NM, Parra-Cabrera S. Association of obesity with physical activity, television programs and other forms of video viewing among children in Mexico city. Int J Obes Relat Metab Disord. 1999 Aug;23(8):845-54. — View Citation

Hocking SL, Stewart RL, Brandon AE, Suryana E, Stuart E, Baldwin EM, Kolumam GA, Modrusan Z, Junutula JR, Gunton JE, Medynskyj M, Blaber SP, Karsten E, Herbert BR, James DE, Cooney GJ, Swarbrick MM. Subcutaneous fat transplantation alleviates diet-induced — View Citation

Klein DA, Boudreau GS, Devlin MJ, Walsh BT. Artificial sweetener use among individuals with eating disorders. Int J Eat Disord. 2006 May;39(4):341-5. — View Citation

Krysiak R, Gdula-Dymek A, Okopien B. Monocyte-suppressing effect of high-dose metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacol Rep. 2013;65(5):1311-6. — View Citation

Lewis HB, Forwood SE, Ahern AL, Verlaers K, Robinson E, Higgs S, Jebb SA. Personal and social norms for food portion sizes in lean and obese adults. Int J Obes (Lond). 2015 Aug;39(8):1319-24. doi: 10.1038/ijo.2015.47. Epub 2015 Apr 14. — View Citation

National Research Council (US). The Public Health Effects of Food Deserts: Workshop Summary. Washington (DC): National Academies Press (US); 2009. — View Citation

Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest. 2006 Jan;116(1):33-5. — View Citation

Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253. — View Citation

Papapanagiotou A, Siasos G, Kassi E, Gargalionis AN, Papavassiliou AG. Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications. Curr Med Chem. 2015;22(23):2727-43. Review. — View Citation

Paredes-Turrubiarte G, González-Chávez A, Pérez-Tamayo R, Salazar-Vázquez BY, Hernández VS, Garibay-Nieto N, Fragoso JM, Escobedo G. Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients. Clin Exp Med. 2016 May;16(2):193-202. doi: 10.1007/s10238-015-0347-4. Epub 2015 Apr 18. — View Citation

Pepino MY, Tiemann CD, Patterson BW, Wice BM, Klein S. Sucralose affects glycemic and hormonal responses to an oral glucose load. Diabetes Care. 2013 Sep;36(9):2530-5. doi: 10.2337/dc12-2221. Epub 2013 Apr 30. — View Citation

Perez-Rodriguez M, Melendez G, Nieto C, Aranda M, Pfeffer F. Dietary and physical activity/inactivity factors associated with obesity in school-aged children. Adv Nutr. 2012 Jul 1;3(4):622S-628S. doi: 10.3945/an.112.001974. — View Citation

Qu HQ, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB. The definition of insulin resistance using HOMA-IR for Americans of Mexican descent using machine learning. PLoS One. 2011;6(6):e21041. doi: 10.1371/journal.pone.0021041. Epub 2011 Jun 14. — View Citation

Stamatakis E, Hillsdon M, Mishra G, Hamer M, Marmot M. Television viewing and other screen-based entertainment in relation to multiple socioeconomic status indicators and area deprivation: the Scottish Health Survey 2003. J Epidemiol Community Health. 2009 Sep;63(9):734-40. doi: 10.1136/jech.2008.085902. Epub 2009 Apr 27. — View Citation

Suárez-Álvarez K, Solís-Lozano L, Leon-Cabrera S, González-Chávez A, Gómez-Hernández G, Quiñones-Álvarez MS, Serralde-Zúñiga AE, Hernández-Ruiz J, Ramírez-Velásquez J, Galindo-González FJ, Zavala-Castillo JC, De León-Nava MA, Robles-Díaz G, Escobedo G. Se — View Citation

Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N, Gilad S, Weinberger A, Kuperman Y, Harmelin A, Kolodkin-Gal I, Shapiro H, Halpern Z, Segal E, Elinav E. Artificial sweeteners induce glucose intolerance by altering the — View Citation

Walther G, Obert P, Dutheil F, Chapier R, Lesourd B, Naughton G, Courteix D, Vinet A. Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction: cross-sectional study. Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):1022-9. doi: 10.1161/ATVBAHA.114.304591. Epub 2015 Feb 5. — View Citation

Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003 Dec;112(12):1796-808. — View Citation

* Note: There are 26 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum insulin levels	To assess the effect of acute and chronic exposure to different sucralose concentrations differentiating the area under the curve levels in healthy, young volunteers, at a glucose tolerance test of 180 minutes.	Change the baseline serum insulin levels at 10 weeks sucralose consumption.
Secondary	C-peptide serum levels.	To assess the effect of acute and chronic exposure to different sucralose concentrations.	Change the baseline serum insulin levels at 10 weeks sucralose consumption.
Secondary	Glucose-dependent insulinotropic polypeptide serum levels.	To assess the effect of acute and chronic exposure to different sucralose concentrations.	Change the baseline serum glucose-dependent insulinotropic polypeptide levels at 10 weeks sucralose consumption.
Secondary	Glucagon serum levels	To assess the effect of acute and chronic exposure to different sucralose concentrations.	Change the baseline serum glucagon levels at 10 weeks sucralose consumption.
Secondary	Glucagon-like peptide-1 serum levels	To assess the effect of acute and chronic exposure to different sucralose concentrations.	Change the baseline serum systemic inflammatory response levels at 10 weeks sucralose consumption.
Secondary	Systemic inflammatory response (pCr, Tumor Necrosis Factor , Internferon -, IL-1, IL-6, IL-12, IL-17, e IL-23 serum levels)	To assess the effect of acute and chronic exposure to different sucralose concentrations.	Change the baseline serum systemic inflammatory response levels at 10 weeks sucralose consumption.
Secondary	Inflammatory monocytes (CD14hiCD16+ CD11c+CCR2hiCX3CR1lowCD206-) serum levels.	To assess the effect of acute and chronic exposure to different sucralose concentrations.	Change the baseline serum inflammatory monocytes levels at 10 weeks sucralose consumption.
Secondary	Anti-inflammatory markers (IL-4, IL-10, e IL-13) serum levels.	To assess the effect of acute and chronic exposure to different sucralose concentrations.	Change the baseline serum anti-inflammatory markers levels at 10 weeks sucralose consumption.
Secondary	Intestinal microbiota composition.	To assess the effect of chronic exposure to different sucralose concentrations.	Change the baseline intestinal microbiota composition at 10 weeks sucralose consumption.
Secondary	Body Mass Index (BMI)	To assess the effect of chronic exposure to different sucralose concentrations.	To compare the baseline body weight at 10 weeks sucralose consumption.
Secondary	Glucose area under the curve levels	Influence of Body Mass Index on the glucose mean area under the curve levels with different sucralose concentrations.	Change the baseline serum glucose levels at 10 weeks sucralose consumption.
Secondary	C-peptide area under the curve levels	Influence of Body Mass Index on the C-peptide mean area under the curve levels with different sucralose concentrations.	Change the baseline serum C-peptide levels at 10 weeks sucralose consumption.
Secondary	Glucagon area under the curve levels	Influence of Body Mass Index on the glucagon mean area under the curve levels with different sucralose concentrations.	Change the baseline serum glucagon levels at 10 weeks sucralose consumption.
Secondary	GLP-1 area under the curve levels	Influence of Body Mass Index on the GLP-1 mean area under the curve levels with different sucralose concentrations.	Change the baseline serum GLP-1 levels at 10 weeks sucralose consumption.
Secondary	Glucose-dependent insulinotropic polypeptide area under the curve levels.	Influence of Body Mass Index on the glucose-dependent insulinotropic polypeptide mean area under the curve levels with different sucralose concentrations.	Change the baseline serum glucose-dependent insulinotropic polypeptide levels at 10 weeks sucralose consumption.

External Links

•   FDA. Food Additives & Ingredients. 2015